Treatment for relapsed or refractory chronic lymphocytic leukaemia: an ongoing challenge

被引：1
|
作者：
Strati, Paolo [1 ]
机构：
[1] Univ Texas Houston, MD Anderson Canc Ctr, Div Canc Med, Houston, TX 77030 USA
来源：
LANCET HAEMATOLOGY | 2017年 / 4卷 / 03期
关键词：
IDELALISIB; FLUDARABINE; RITUXIMAB;
D O I：
10.1016/S2352-3026(17)30020-0
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E97 / E98
页数：2
相关论文
共 50 条
  • [31] Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma
    Costa, Luciano J.
    Fanning, Suzanne R.
    Stephenson, Joe, Jr.
    Afrin, Lawrence B.
    Kistner-Griffin, Emily
    Bentz, Tricia A.
    Stuart, Robert K.
    LEUKEMIA & LYMPHOMA, 2015, 56 (03) : 645 - 649
  • [32] Current Treatment Options in Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: a Review
    Prioty Islam
    Current Treatment Options in Oncology, 2023, 24 : 1259 - 1273
  • [33] Patient experience in relapsed/ refractory chronic lymphocytic leukaemia UK clinical practice: Study methodology overview
    El Sharkawi, Dima
    Johnston, Charlotte
    Martins, Daniel
    Kent, Toby
    Powell, Louise
    Manzoor, Beenish
    Fuldeore, Mahesh
    McCarrier, Kelly
    Kelly, Jo
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 147 - 148
  • [34] Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemia
    Hansson, Lotta
    Asklid, Anna
    Diels, Joris
    Eketorp-Sylvan, Sandra
    Repits, Johanna
    Soltoft, Frans
    Jaeger, Ulrich
    Osterborg, Anders
    ANNALS OF HEMATOLOGY, 2017, 96 (10) : 1681 - 1691
  • [35] Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemia
    Lotta Hansson
    Anna Asklid
    Joris Diels
    Sandra Eketorp-Sylvan
    Johanna Repits
    Frans Søltoft
    Ulrich Jäger
    Anders Österborg
    Annals of Hematology, 2017, 96 : 1681 - 1691
  • [36] COST-EFFECTIVENESS OF IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY (RR) CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) IN ENGLAND
    Hassan, F.
    Peng, S.
    Dorman, E.
    Sorensen, S.
    Thompson, G.
    Lee, J.
    VALUE IN HEALTH, 2017, 20 (09) : A441 - A441
  • [37] Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study
    Seymour, John F.
    Ma, Shuo
    Brander, Danielle M.
    Choi, Michael Y.
    Barrientos, Jacqueline
    Davids, Matthew S.
    Anderson, Mary Ann
    Beaven, Anne W.
    Rosen, Steven T.
    Tam, Constantine S.
    Prine, Betty
    Agarwal, Suresh K.
    Munasinghe, Wijith
    Zhu, Ming
    Lash, L. Leanne
    Desai, Monali
    Cerri, Elisa
    Verdugo, Maria
    Kim, Su Young
    Humerickhouse, Rod A.
    Gordon, Gary B.
    Kipps, Thomas J.
    Roberts, Andrew W.
    LANCET ONCOLOGY, 2017, 18 (02): : 230 - 240
  • [38] Undetectable minimal residual disease should be the goal of venetoclax therapy in relapsed and refractory chronic lymphocytic leukaemia
    Lew, Thomas
    Anderson, Mary Ann
    Lin, Victor
    Handunnetti, Sasanka
    Came, Neil
    Westerman, David
    Meaghan, Wall
    Tam, Constantine
    Roberts, Andrew W.
    Seymour, John F.
    LEUKEMIA & LYMPHOMA, 2020, 61 : 172 - 174
  • [39] Patient experience in relapsed/refractory chronic lymphocytic leukaemia UK clinical practice: Study methodology overview
    El Sharkawi, Dima
    Johnston, Charlotte
    Martins, Daniel
    Kent, Toby
    Powell, Louise
    Manzoor, Beenish
    Fuldeore, Mahesh
    McCarrier, Kelly
    Kelly, Jo
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 147 - 148
  • [40] A challenge to the claims that fludarabine and cyclophosphamide is the new standard treatment for chronic lymphocytic leukaemia
    Haines, I.
    Elliott, P.
    Stanley, R.
    INTERNAL MEDICINE JOURNAL, 2009, 39 (04) : 269 - 271
12345